75. クッシング病 Cushing disease Clinical trials / Disease details

臨床試験数 : 203 /  薬物数 : 191 - (DrugBank : 51) / 標的遺伝子数 : 62 - 標的パスウェイ数 : 128

  
2 trials found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT03145285
(ClinicalTrials.gov)		April 18, 201726/4/2017Activity of Abiraterone Acetate in the Management of Cushing's Syndrome in Patients With Adrenocortical CarcinomaActivity of Abiraterone Acetate in the Management of Cushing's Syndrome in Patients With Adrenocortical CarcinomaCushing Syndrome;Adrenocortical CarcinomaDrug: Abiraterone AcetateAzienda Ospedaliera Spedali Civili di BresciaFondazione IRCCS Istituto Nazionale dei Tumori, Milano;Niguarda Hospital;San Camillo Hospital, Rome;San Luigi Gonzaga HospitalActive, not recruiting18 YearsN/AAll10Phase 2Italy
2EUCTR2016-000945-29-IT
(EUCTR)		16/06/201604/11/2020Activity of Abiraterone Acetate in the management of Cushing’s syndrome in patients with adrenocortical carcinoma (ABACUS)Activity of Abiraterone Acetate in the management of Cushing’s syndrome in patients with adrenocortical carcinoma (ABACUS) - ABACUS Cushing’s syndrome in patients with adrenocortical carcinoma
MedDRA version: 20.0;Level: PT;Classification code 10001388;Term: Adrenocortical carcinoma;System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps);Therapeutic area: Diseases [C] - Cancer [C04]		Trade Name: ZYTIGA - 250 MG - COMPRESSA - USO ORALE - FLACONE 120 COMPRESSE
Product Name: ZYTIGA
Product Code: [ZYTIGA]
INN or Proposed INN: abiraterone acetato		AZIENDA SOCIO SANITARIA TERRITORIALE DEGLI SPEDALI CIVILI DI BRESCIANULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes		30Phase 2Italy